Foldax is engages in synthetic heart valve development to deliver non-thrombogenic aortic and mitral valves at dramatically lower cost.
Foldax has raised $7.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2023.
Foldax's investors include Caltech, Kairos Ventures, BioStar Capital, MemorialCare Innovation Fund, Angel Physicians Fund.
Foldax is headquartered in Salt Lake City, United States.
Foldax is engages in synthetic heart valve development to deliver non-thrombogenic aortic and mitral valves at dramatically lower cost.
Foldax is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Foldax — Funding & Investors." VCBacked, November 7, 2023, https://www.vcbacked.co/company/foldax. Accessed November 12, 2026.
VCBacked. (2023). Foldax — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/foldax
{{cite web |title=Foldax — Funding & Investors |url=https://www.vcbacked.co/company/foldax |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Foldax? Request a listing update